ghk-cu topical tolerance desensitization ghk cu antibody formation long term use Peptide: Clinical Evidence & Injectable Protocols GHK‐Cu protects mice against CS‐induced – ghk-cu tolerance desensitization topical use

They are applied topically (not injected) and are classified as a cosmetic product rather than a prescription medicine

The naturally occurring peptide GHK-Cu (GHK from glycyl-L-histidyl-L-lysine bound to a copper ion), which affects 31.2% of the human genes by either activating or deactivating them (based on a criterion of a reduction or increment in gene activity of more than 50%), meaning that it works by inducing epigenetic alterations in the cells

Research in mammalian models demonstrates plasma GHK-Cu concentrations of approximately 200 ng/mL in young organisms, with these levels declining dramatically with age to around 80 ng/mL in aged specimens

For Australian consumers, brands that combine high purity with cost-efficiency, such as PeptideTechs hybrid method (98.8% purity at 18% lower cost), are gaining market share

18 peer-reviewed citations verified against primary literature between March and May 2026

Delivery Mechanism Studies : Investigating device-based administration parameters and release kinetics for combined peptide formulations in vitro